ATE142262T1 - Gegen das menschliche immunschwäche-virus gerichtetes immunpräparat - Google Patents

Gegen das menschliche immunschwäche-virus gerichtetes immunpräparat

Info

Publication number
ATE142262T1
ATE142262T1 AT92109072T AT92109072T ATE142262T1 AT E142262 T1 ATE142262 T1 AT E142262T1 AT 92109072 T AT92109072 T AT 92109072T AT 92109072 T AT92109072 T AT 92109072T AT E142262 T1 ATE142262 T1 AT E142262T1
Authority
AT
Austria
Prior art keywords
directed against
deficiency virus
human immuno
immuno deficiency
immune preparation
Prior art date
Application number
AT92109072T
Other languages
English (en)
Inventor
Yasuyuki Eda
Kouichi Shiosaki
Kiyoshi Osatomi
Sachio Tokiyoshi
Original Assignee
Chemo Sero Therapeut Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Sero Therapeut Res Inst filed Critical Chemo Sero Therapeut Res Inst
Application granted granted Critical
Publication of ATE142262T1 publication Critical patent/ATE142262T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4216—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig
    • C07K16/4225—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig against anti-HIV Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/425—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-protozoal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT92109072T 1991-05-31 1992-05-29 Gegen das menschliche immunschwäche-virus gerichtetes immunpräparat ATE142262T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP3129224A JPH0570493A (ja) 1991-05-31 1991-05-31 ヒト免疫不全ウイルス（ｈｉｖ）関連免疫調製物

Publications (1)

Publication Number Publication Date
ATE142262T1 true ATE142262T1 (de) 1996-09-15

Family

ID=15004222

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92109072T ATE142262T1 (de) 1991-05-31 1992-05-29 Gegen das menschliche immunschwäche-virus gerichtetes immunpräparat

Country Status (10)

Country Link
EP (1) EP0516135B1 (de)
JP (1) JPH0570493A (de)
KR (1) KR920021164A (de)
AT (1) ATE142262T1 (de)
AU (1) AU659839B2 (de)
CA (1) CA2069671A1 (de)
DE (1) DE69213325T2 (de)
DK (1) DK0516135T3 (de)
ES (1) ES2094252T3 (de)
GR (1) GR3021618T3 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2730493B1 (fr) * 1995-02-09 1997-04-18 Pasteur Institut Polypeptides de glycoproteine transmembranaire d'enveloppe du retrovirus humain du type hiv-1 et polypeptides presentant avec eux une parente immunologique
US6428790B1 (en) 1995-04-27 2002-08-06 The United States Of America As Represented By The Secretary Department Of Health And Human Services Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
US6780847B2 (en) 1995-04-27 2004-08-24 The United States Of America As Represented By The Department Of Health And Human Services Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins
US6193982B1 (en) 1995-04-27 2001-02-27 The United States Of America As Represented By The Department Of Health & Human Services Anti-cyanovirin antibody with an internal image of gp120, a method of use thereof, and a method of using a cyanovirin to induce an immune response to gp120
US6987096B1 (en) 1995-04-27 2006-01-17 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides, DNA coding sequences therefor, and uses thereof
US7048935B2 (en) 1995-04-27 2006-05-23 The United States Of America As Represented By The Department Of Health And Human Services Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
US5843882A (en) 1995-04-27 1998-12-01 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides
IT1312061B1 (it) * 1999-04-09 2002-04-04 Diapharm Ltd Sequenza nucleotidica per la rivelazione e caratterizzazione diisolati ospedalieri di hiv-1 che partecipano nei processi di
CA2441287C (en) 2001-03-22 2014-06-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU623097B2 (en) * 1987-10-09 1992-05-07 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Oligopeptides and their use for diagnostic and vaccination purposes for aids and arc
NL8702403A (nl) * 1987-10-09 1989-05-01 Stichting Centr Diergeneeskund Oligopeptiden en gebruik daarvan voor diagnostische en vaccinatiedoeleinden voor aids en arc.
EP0436634A1 (de) * 1988-10-03 1991-07-17 Repligen Corporation Hiv-proteine und peptide und deren verwendung zur diagnose, prophylaxe und therapie von aids

Also Published As

Publication number Publication date
DE69213325T2 (de) 1997-03-20
JPH0570493A (ja) 1993-03-23
DE69213325D1 (de) 1996-10-10
EP0516135A3 (en) 1993-05-05
AU659839B2 (en) 1995-06-01
EP0516135B1 (de) 1996-09-04
CA2069671A1 (en) 1992-12-01
DK0516135T3 (da) 1996-09-23
AU1715292A (en) 1992-12-17
ES2094252T3 (es) 1997-01-16
GR3021618T3 (en) 1997-02-28
EP0516135A2 (de) 1992-12-02
KR920021164A (ko) 1992-12-18

Similar Documents

Publication Publication Date Title
DE69126301D1 (de) Hiv-induzierte synzytien blockierender anti-cd-4-antikörper
EP2280072A3 (de) Gruppe B-Streptococcus Antigene
CA2143163A1 (en) Peptides derived from a retrovirus of the hiv group, and their use
DK0523395T3 (da) Seroreaktive områder på proteinerne E1 og E2 i HPV 16
CA2066661A1 (en) Viral vaccine conjugates
DE69213325D1 (de) Gegen das menschliche Immunschwäche-Virus gerichtetes Immunpräparat
CA2192512A1 (en) Nm03 antibody materials and methods
CA2129747A1 (en) Peptide for diagnosing and immunizing against t. cruzi infection
AU8010791A (en) Hiv monoclonal antibody
DE3782771D1 (de) Gegen pseudomonas aeruginosa infektionen wirksame praeparationen und verfahren zu ihrer herstellung.
DK0431327T3 (da) Syntetisk vaccine til specifik induktion af cytotoksiske T-lymfocytter
EP0293827A3 (de) Probe für Leishmaniosis
PT91316A (pt) Processo para a preparacao de vectores recombinantes e de particulas hbsag recombinantes hibridas tendo as caracteristicas morfologicas do antigenio hbsag contendo uma sequencia imunogenica que induz anticorpos neutralizantes dirigidos contra hiv ou susceptivel de ser reconhecida por tais anticorpos
DE69011122D1 (de) Rubella-e1 und c peptide.
ES2095258T3 (es) Nuevo virus de la enfermedad de la bolsa infecciosa.
DE69113520D1 (de) Monoklonale Antikörper gegen HIV GP120.
FR2640511B1 (fr) Medicaments pour le traitement ou la prevention par immunisation passive de l'infection par le virus hiv et procede de preparation
Morozov et al. The Use of Thymic Peptides for Patients with Undetermined Human Immunodeficiency Virus
BR9711809A (pt) Polipeptìdeo antigênico ou imunogênico, processos para tratar ou prevenir uma doença ou distúrbio em um indivìduo provocado por infecção com htlv-i, e com htlv-ii, para elicitar em um indivìduo a produção de anticorpos que especificamente ligam-se às proteìnas envelopes htlv-ii e htlv-i, e, para gerar uma resposta imune em um indivìduo
Lever et al. Presence of a partially acid‐labile alpha‐interferon in bronchoalveolar lavage fluid of patients with cytomegalovirus pneumonitis is associated with a poor prognosis
ATE103817T1 (de) Gegen pseudomonas aeruginosa-infektionen wirksame praeparationen sowie immunglobulin-g-haeltige, gegen bakterium pseudomonas aeruginosa wirksame praeparationen.
Grundy et al. Production of a Partially Acid Labile Alpha Interferon in Cytomegalovirus Pneumonitis
SE9202318D0 (sv) Nya peptider, diagnostiska antigen, anvaendning daerav, vacciner och medikamenter
Egorenkova et al. Use of enzyme-immunoassay with Staphylococcus protein A/peroxidase conjugate in serodiagnosis of influenza.
RU96123360A (ru) Способ лечения сепсиса у новорожденных

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee